Kane Biotech (CVE:KNE) Sets New 12-Month Low – Here’s What Happened

Shares of Kane Biotech Inc. (CVE:KNE) hit a new 52-week low during trading on Thursday . The stock traded as low as C$0.09 and last traded at C$0.09, with a volume of 11500 shares traded. The stock had previously closed at C$0.10.

Kane Biotech Stock Performance

The company has a market cap of C$14.41 million, a PE ratio of 2.50 and a beta of 0.52. The stock’s 50 day simple moving average is C$0.10 and its two-hundred day simple moving average is C$0.11. The company has a quick ratio of 0.39, a current ratio of 0.80 and a debt-to-equity ratio of -331.42.

Insider Transactions at Kane Biotech

In other news, Director Marc Edwards acquired 2,000,000 shares of Kane Biotech stock in a transaction dated Friday, January 17th. The shares were acquired at an average cost of C$0.10 per share, with a total value of C$200,000.00. Insiders own 37.21% of the company’s stock.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.